Varenicline for Quitting Smoking: How It Works and Who It Suits

Most of the clients I coach have already heard of the pill. They know it as Champix, or as Chantix if they have spent time in the United States, and they tend to arrive with either a firm opinion or a quiet fear attached to it. A brother quit on it in a fortnight. A frightening headline read sometime around 2009 that never quite left. Very few arrive actually knowing what varenicline does, which is a shame, because it is one of the most effective tools in the cessation toolkit and the fog around it has cost a lot of quitters a path that would have worked for them.

This article is the doctor-led account of what varenicline is, the mechanism that makes it work, what the first two weeks tend to feel like, the neuropsychiatric question and what the evidence now says about it, and who the medication actually suits. It is the deep-dive companion to cold turkey versus NRT, which compares the dose paths from a height. This one goes inside the prescription path.

What varenicline actually is

The first thing to be clear about: varenicline is not nicotine replacement. NRT, the patch and the gum and the lozenge, delivers nicotine itself at a lower and steadier dose than a cigarette. Varenicline contains no nicotine at all. It is a different kind of molecule doing a different kind of job.

It is a partial agonist at the nicotinic receptor, the same receptor in the brain that a cigarette acts on. Partial agonist is worth unpacking, because the word is doing two jobs at once.

It takes the edge off withdrawal. By sitting on the receptor and producing a mild signal of its own, varenicline gives the brain a small fraction of what it is asking for during withdrawal. Far less than a cigarette, but enough that the receptor adaptation on Day 3 does not arrive with the full force it would in an unaided quit. The wall is still there. It is lower.

It blunts the reward of a slip. This is the part most people have never had explained to them, and it is the cleverer half. Because varenicline is already occupying the receptor, a cigarette smoked on top of it has nowhere useful to land. The nicotine cannot bind and produce its usual hit. Clients who lapse while on varenicline almost always describe the cigarette the same way: flat, pointless, not worth it. For a quitter whose failure pattern is the just one that quietly becomes ten, that flatness is genuinely protective. It keeps a lapse a lapse instead of letting it become the relapse.

The numbers, in plain English

The published evidence on varenicline is large and consistent. Pooled across the trials and the Cochrane reviews, varenicline roughly doubles to triples the odds of being quit at six months compared with an unaided attempt, with the relative risk landing somewhere around 2.3 against placebo.

Head to head, it performs better than a single form of NRT used on its own, better than bupropion, and roughly on par with combination NRT, meaning a long-acting patch plus a short-acting gum or lozenge. It is, in other words, one of the two most effective pharmacological paths available, the other being combination NRT.

The honest framing matters here. Of one hundred quitters using varenicline alongside a real behavioural plan, the published range puts somewhere between ten and twenty quit at the twelve-month mark. That is triple the unaided rate, and it is still most people not making it. The medication improves the odds meaningfully. It does not remove the work. Any coach who tells you a pill makes quitting easy is selling you something, and what they are selling you will break around Day 4 like every unsupported quit before it.

What the standard course looks like

Before this section: the actual decision belongs to your prescriber. What follows is the standard course, described so that you know what to expect when you have the conversation, not as instructions to act on yourself.

The most important structural feature of varenicline is that you do not start it on your quit day. You start it about a week before. The standard course opens with a short titration, a low dose for the first few days stepping up across the first week to the full maintenance dose at around Day 8, and the quit date is usually set for that Day 8 once the drug has reached steady state in the body. This is the opposite of NRT, which you begin on the morning you stop. With varenicline the medication goes first and the cigarette goes second.

The standard course runs twelve weeks. For people who reach twelve weeks quit, the evidence supports an optional further twelve weeks of maintenance to lower the risk of late relapse, and that is a conversation worth having with the prescriber rather than defaulting to stopping at week twelve.

Two variations are worth knowing exist. The first is a flexible quit date, setting the quit day anywhere in the first five weeks rather than rigidly at Day 8, which suits people who want to feel the medication settle before they commit. The second is gradual reduction, starting varenicline while still smoking and cutting down over a longer window before stopping fully. Both have trial support. Both are prescriber conversations, not self-directed choices.

One genuinely practical thing the leaflet underplays: take it with food and a full glass of water. That single habit is the biggest lever you have over the most common side effect, which brings us to the next part.

The first two weeks

Nausea is the one you are most likely to meet. Roughly a third of people on varenicline notice it. It is usually mild, usually dose-related, and usually settles after the first week or two as the body adjusts. Taking the dose with food blunts it considerably. If it is genuinely hard to tolerate, the prescriber can drop you to the lower dose rather than stopping the medication outright, and most people do not need to.

Vivid, strange, occasionally cinematic dreams are the side effect clients remark on most. They are common, usually harmless, and for some people frankly entertaining. If the dreams are disturbing sleep, taking the evening dose a little earlier often helps.

Less commonly, people notice some insomnia, headache, or constipation. These are usually manageable and usually fade. The pattern across all of it is that the side effects are front-loaded into the first weeks and then ease. The people who abandon varenicline early most often do so in week one because of nausea, and nausea is the most preventable item on the whole list. Knowing that in advance is most of the fix.

The neuropsychiatric question

This is the part clients are most afraid of, so it deserves a straight and complete answer rather than a reassuring half of one.

In 2009, regulators added a boxed warning to varenicline, the most serious category of medication warning, covering reports of mood changes, depression, agitation and suicidal thoughts in some people taking it. That warning made headlines, and those headlines are still doing work in 2026. A large share of the fear clients bring to the discovery call traces straight back to a news story from over fifteen years ago.

What changed is that the question got tested properly. A large randomised trial designed specifically to answer it, known as the EAGLES trial and published in 2016, followed thousands of smokers, including a substantial group with stable psychiatric conditions. It did not find a significant increase in serious neuropsychiatric events on varenicline compared with placebo or with NRT. On the strength of that evidence, the FDA removed the boxed warning later that same year.

So the honest position now is two-sided. Varenicline is not the danger the 2009 headline made it out to be, and a quitter who rules it out purely on the strength of that memory is ruling out a path on outdated information. But no longer boxed is not the same as ignore your mood entirely. Anyone with a history of depression or another psychiatric condition should make that history an explicit part of the prescriber conversation. And anyone at all, history or not, should treat a real shift in mood while taking it as a reason to call their doctor rather than push through quietly. Quitting itself can lower mood in the early weeks, with or without medication, and that is worth watching for on every path, not only this one.

Who varenicline suits, and who should think twice

In my experience it tends to suit a few clear groups. Heavier or longer-term smokers, for whom the lower-force Day 3 is a meaningful difference. People who have used NRT properly, at a real dose, and relapsed anyway. People who specifically want a path with no nicotine in it at all. And people whose failure pattern is the slip that snowballs, because the way varenicline flattens that first lapse cigarette is, for them, the most useful thing it does.

It needs a more careful conversation in a few situations. Pregnancy or planned pregnancy, where NRT is generally the preferred route and varenicline is not first-line. A significant psychiatric history, which does not rule it out but does change the monitoring around it. And significant kidney impairment, where the dose is adjusted. None of these are reasons the medication is off the table. They are reasons the prescriber needs the full picture before routing you, which is the entire point of the appointment.

What I would not do is rank the paths as if varenicline sits above combination NRT. It does not, particularly. They are close in the evidence, and the better path is genuinely the one a given person will actually complete. For some people the patch-and-lozenge route fits their life and their preferences better, and that fit is worth more than a small difference in a pooled trial average. This article is not selling the pill. It is making sure the pill is understood, because being misunderstood is the only reason it gets ruled out unfairly.

One footnote for the curious: varenicline has an older, plant-derived relative called cytisine, used for decades in parts of Eastern Europe and now studied more widely. Same receptor family, same basic idea. If your prescriber raises it, it is not an exotic substitute, it is a cousin.

Varenicline is the chemistry, not the plan

Everything above is the chemistry, and the chemistry is real. But the medication occupies a receptor. It does not occupy the chair at the cafe, the ten minutes after dinner, the drive home from work, the wedding, or the colleague who still steps outside at 3pm and tilts his head at you on the way past.

Varenicline makes Day 3 survivable for far more people than would survive it unaided. It does not draw the trigger map, rebuild the social occasions where the habit used to live, or do the identity work that has to be load-bearing by Day 30. Those are behavioural surfaces, and they are most of why medication plus structured coaching outperforms medication alone.

There is a risk specific to varenicline worth naming. Because it works so cleanly for some people in the first weeks, they skip the behavioural plan entirely. The medication is doing the visible work, so the invisible work feels unnecessary. Then the twelve-week course tapers out, and there is nothing underneath it. The relapse curve after a medication course ends is real, and it is steepest for the people who never built the scaffolding while the drug was carrying them. The behavioural side is supposed to be the load-bearing part by the time the chemistry steps back.

What to do this week

Five things, in order:

1. Book the GP or pharmacist conversation. Varenicline is prescription-only, so that conversation is the gate. Book it early, because the course starts roughly a week before your quit day and the timing only works if you plan backwards from it.
2. Bring your history. Psychiatric history, kidney issues, pregnancy plans, other medications. These are exactly what determine whether varenicline, combination NRT, or another path is the right fit, and the prescriber can only route you well if they have the whole picture in front of them.
3. Pick the quit date after you know the start date. With varenicline the quit day sits about a week into the course, not on Day 1. Count forward from when you can realistically begin.
4. Read the timeline anyway. The withdrawal timeline still applies. Varenicline softens the curve. It does not delete it, and knowing what each day holds still helps.
5. Build the behavioural side in parallel. The trigger map, the substitute behaviour, the household conversation, the Habit Breaker for the social settings. The medication buys you a calmer Day 3. The behaviour is what keeps you quit after week twelve.

Varenicline is not a quit on its own. It is a much lower wall on Day 3, and a much flatter cigarette if you slip. What you build on top of that calm is still the actual quit, and that is the part the structured programme on this site exists to do with you: the NRT-or-varenicline decision made properly in the first session, the trigger map, the Habit Breaker, the Day 21 receptor reset, and the identity work that becomes the load-bearing part by Day 30.

A note: varenicline dosing, contraindications, interactions, and the monitoring around mood and existing conditions all belong to your prescriber. The figures in this article are population averages from the published literature, and the standard course is described so you know what to expect, not as a plan to follow without that conversation. Bring the decision to whoever knows your full clinical picture.